Last reviewed · How we verify

NCT03899974

Metabolic Effects of High-amylose Wheat-based Breads

Completed NA Last updated 4 December 2019
What this trial tests

NA trial testing Test meal in Postprandial Hyperglycemia in 20 participants. Completed in 31 July 2019.

Timeline
1 March 2018
Primary endpoint
15 December 2018
31 July 2019

Quick facts

Lead sponsorFederico II University
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designcrossover
Maskingtriple
Primary purposeprevention
Enrollment20
Start date1 March 2018
Primary completion15 December 2018
Estimated completion31 July 2019
Sites1 location across Italy

Drugs / interventions tested

Conditions studied

Sponsor

Federico II University

Who can join

Adults 18 to 70, any sex, with Postprandial Hyperglycemia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The amylose-amylopectin ratio influences starch properties. A higher amylose content is associated with slower starch digestion thus reducing the postprandial plasma glucose response and improving the overall postprandial metabolism. So far, limited evidence is available on the metabolic effect of wheat-based foods rich in amylose. This randomised controlled study investigated the acute metabolic effects of amylose-rich wheat-based breads in overweight subjects focusing on potential mechanisms.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. High Amylose Wheat Bread at Breakfast Increases Plasma Propionate Concentrations and Reduces the Postprandial Insulin Response to the Following Meal in Overweight Adults.
    Costabile G, Vetrani C, Calabrese I, Vitale M, et al · · 2023 · cited 6× · PMID 36913446 · DOI 10.1016/j.tjnut.2022.10.007

Verify or expand the search:

Other trials of Test meal

Trials testing the same drug.

Other recruiting trials for Postprandial Hyperglycemia

Currently open trials in the same condition.

Other Federico II University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03899974.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing